← ANALYST RATINGS · TIPRANKS
Stryker (SYK): analyst forecast and price target
Analyst consensus
Strong Buy9 Buy2 Hold0 Sell
Ratings of 11 analysts in the last 3 months · top analysts only12-month forecast
Based on 11 price targets given in the last 3 months, the average target is $361, the highest $418, the lowest $298. The average is +22.4% from the last price of $295.
Analyst ratings 29
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Caitlin Roberts★★★★★★★★★★#1832 · hits 65% · avg +14.7% | Canaccord Genuity | $385 | Buy | +30.7% | Reiterated | 13.10.26on TipRanks 07:15 | 0.0%next day +0.8% | ↗ |
| Christopher Pasquale★★★★★★★★★★#1776 · hits 61% · avg +11.9% | Nephron | $375 | Buy | +27.3% | Reiterated | 13.10.26on TipRanks 04:50 | 0.0%next day +0.8% | ↗ |
| Vik Chopra★★★★★★★★★★#6076 · hits 45% · avg +1.9% | BMO Capital | $317 | Buy | +7.6% | Reiterated | 12.10.26on TipRanks Oct 13 08:15 | +2.0%next day 0.0% | ↗ |
| Ryan Zimmerman★★★★★★★★★★#3375 · hits 46% · avg +3.3% | BTIG | $358 → $316−11.7% | Buy | +7.2% | Reiterated | 12.10.26on TipRanks 08:40 | +2.0%next day 0.0% | ↗ |
| Mike Kratky★★★★★★★★★★#1691 · hits 46% · avg +12.9% | Leerink Partners | $403 → $353−12.4% | Buy | +19.8% | Assigned | 12.10.26on TipRanks 07:35 | +2.0%next day 0.0% | ↗ |
| Joanne Wuensch★★★★★★★★★★#3684 · hits 55% · avg +2.3% | Citi | — | Buy | — | Reiterated | 07.10.26on TipRanks 10:00 | −0.8%next day +1.0% · 5 days +3.2% | ↗ |
| Matt Miksic★★★★★★★★★★#2645 · hits 55% · avg +3.9% | Barclays | $375 | Buy | +27.3% | Initiated | 07.10.26on TipRanks 03:55 | −0.8%next day +1.0% · 5 days +3.2% | ↗ |
| AI xAi Medical - DevicesxAI Grok-3 | TipRanks - xAI | $310 → $321+3.5% | Buy | +8.9% | Reiterated | 07.10.26on TipRanks Oct 6 23:05 | — | |
| AI DeepSeek Medical - DevicesDeepSeek R1-0528 | TipRanks - DeepSeek | $300 → $317+5.7% | Buy | +7.6% | Upgrade | 07.10.26on TipRanks Oct 6 23:05 | — | |
| AI OpenAI Medical - DevicesOpenAI 4o | TipRanks - OpenAI | $304 → $318+4.6% | Buy | +7.9% | Reiterated | 07.10.26on TipRanks Oct 6 23:05 | — | |
| AI Anthropic Medical - DevicesAnthropic Opus-4.1 | TipRanks - Anthropic | $297 → $307+3.4% | Hold | +4.2% | Reiterated | 07.10.26on TipRanks Oct 6 23:05 | — | |
| AI Google Medical - DevicesGemini 2.5Pro | TipRanks - Google | $314 → $317+1.0% | Buy | +7.6% | Reiterated | 07.10.26on TipRanks Oct 6 23:05 | — | |
| AI PerPlexity Medical - DevicesPerPlexity SonarPro | TipRanks - PerPlexity | $307 → $323+5.2% | Buy | +9.6% | Reiterated | 07.10.26on TipRanks Oct 6 23:05 | — | |
| Travis Steed★★★★★★★★★★#3596 · hits 53% · avg +3.0% | Bank of America Securities | $380 | Buy | +29.0% | Reiterated | 06.10.26on TipRanks Oct 7 06:45 | −3.0%next day −0.8% · 5 days +1.7% | ↗ |
| Richard Newitter★★★★★★★★★★#1772 · hits 48% · avg +6.6% | Truist Financial | $340 → $310−8.8% | Hold | +5.2% | Reiterated | 06.10.26on TipRanks 12:50 | −3.0%next day −0.8% · 5 days +1.7% | ↗ |
| Michael Matson★★★★★★★★★★#1853 · hits 50% · avg +6.0% | Needham | $418 | Buy | +41.9% | Reiterated | 06.10.26on TipRanks 10:55 | −3.0%next day −0.8% · 5 days +1.7% | ↗ |
| Name not given | — | $420 | Buy | +42.5% | Reiterated | 01.10.26on TipRanks Oct 2 21:45 | −1.1%next day +0.2% · 5 days +0.2% | ↗ |
| Rick Wise★★★★★★★★★★#7800 · hits 51% · avg +0.1% | Stifel Nicolaus | $360 → $330−8.3% | Buy | +12.0% | Reiterated | 30.09.26on TipRanks 06:50 | −0.7%next day −1.1% · 5 days −1.9% | ↗ |
| Matthew Taylor★★★★★★★★★★#1367 · hits 55% · avg +7.2% | Jefferies | $405 | Buy | +37.4% | Reiterated | 22.09.26on TipRanks 08:55 | +0.3%next day +0.1% · 5 days +2.5% | ↗ |
| Mathew Blackman★★★★★★★★★★#2177 · hits 49% · avg +9.2% | TD Cowen | $355 → $298−16.1% | Hold | +1.1% | Assigned | 22.09.26on TipRanks 07:50 | +0.3%next day +0.1% · 5 days +2.5% | ↗ |
| Shagun Singh Chadha★★★★★★★★★★#9557 · hits 48% · avg −0.4% | RBC Capital | $420 | Buy | +42.5% | Reiterated | 16.09.26on TipRanks Sep 17 07:10 | +1.6%next day −2.8% · 5 days −6.1% | ↗ |
| Larry Biegelsen★★★★★★★★★★#2729 · hits 53% · avg +3.8% | Wells Fargo | $348 | Buy | +18.1% | Assigned | 16.09.26on TipRanks 06:35 | +1.6%next day −2.8% · 5 days −6.1% | ↗ |
| Steven Lichtman★★★★★★★★★★#568 · hits 54% · avg +14.7% | William Blair | — | Buy | — | Reiterated | 09.09.26on TipRanks 10:19 | +0.1%next day −1.4% · 5 days +4.5% | ↗ |
| Robbie Marcus★★★★★★★★★★#1974 · hits 51% · avg +6.5% | J.P. Morgan | $350 | Buy | +18.8% | Reiterated | 04.08.26on TipRanks Aug 5 08:10 | −3.3%next day +0.5% · 5 days +3.7% | ↗ |
| David Turkaly★★★★★★★★★★#11791 · hits 40% · avg −4.0% | Citizens JMP | $440 → $400−9.1% | Buy | +35.7% | Reiterated | 03.08.26on TipRanks 08:55 | +3.3%next day −3.3% · 5 days −0.7% | ↗ |
| Jayson Bedford★★★★★★★★★★#819 · hits 60% · avg +8.6% | Raymond James | $383 → $370−3.4% | Buy | +25.6% | Reiterated | 31.07.26on TipRanks 09:00 | −7.1%next day +3.3% · 5 days +0.6% | ↗ |
| Matthew O'Brien★★★★★★★★★★#12031 · hits 41% · avg −4.5% | Piper Sandler | $420 → $390−7.1% | Buy | +32.4% | Reiterated | 31.07.26on TipRanks 07:26 | −7.1%next day +3.3% · 5 days +0.6% | ↗ |
| Patrick Wood★★★★★★★★★★#10768 · hits 50% · avg −2.1% | UBS | $380 → $400+5.3% | Buy | +35.7% | Upgrade | 28.07.26on TipRanks 06:51 | +2.7%next day +3.2% · 5 days −7.2% | ↗ |
| David Toung★★★★★★★★★★#1098 · hits 63% · avg +9.1% | Argus Research | $350 → $370+5.7% | Buy | +25.6% | Assigned | 09.07.26on TipRanks 09:31 | −0.8%next day +0.4% · 5 days +1.4% | ↗ |
| Vijay Kumar★★★★★★★★★★#2375 · hits 54% · avg +4.8% | Evercore ISI | $355 → $350−1.4% | Buy | +18.8% | Reiterated | 06.07.26on TipRanks 08:55 | −1.4%next day +2.0% · 5 days +2.4% | ↗ |
| David Roman★★★★★★★★★★#3715 · hits 53% · avg +5.3% | Goldman Sachs | $357 → $361+1.1% | Hold | +22.5% | Reiterated | 01.05.26on TipRanks 19:50 | −0.9%next day +0.7% · 5 days −5.8% | ↗ |
| Jeff Johnson★★★★★★★★★★#1125 · hits 51% · avg +10.4% | Robert W. Baird | $437 → $385−11.9% | Buy | +30.7% | Reiterated | 01.05.26on TipRanks 09:00 | −6.8%next day −0.9% · 5 days −5.5% | ↗ |
| Pito Chickering★★★★★★★★★★#1500 · hits 61% · avg +9.8% | Deutsche Bank | $402 → $315−21.6% | Hold | +6.9% | Reiterated | 01.05.26on TipRanks 07:35 | −6.8%next day −0.9% · 5 days −5.5% | ↗ |
| Lee Hambright★★★★★★★★★★#10167 · hits 49% · avg −1.6% | Bernstein | $465 → $410−11.8% | Buy | +39.1% | Reiterated | 01.05.26on TipRanks 07:10 | −6.8%next day −0.9% · 5 days −5.5% | ↗ |
| Nico Chen★★★★★★★★★★#2913 · hits 59% · avg +9.8% | DBS | $450 | Buy | +52.7% | Reiterated | 18.03.26on TipRanks Mar 19 07:20 | +0.5%next day −1.5% · 5 days −4.8% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Stryker
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $368 at a price of $275 (+33.6%); now: $365 at $295 (+23.8%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 0 | 0 | 1 |
| Buy | 17 | 12 | 19 | 13 | 16 | 11 |
| Hold | 6 | 4 | 5 | 2 | 3 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 29.10.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $3.55 (from $3.44 to $3.79). Last quarter: $3.69.
Sales
Next quarter’s sales estimate — $6.6B (from $6.5B to $6.7B). Last quarter: $6.6B.
Best top-analyst consensus in the sector · Healthcare
About Stryker
- CEO: Kevin A. Lobo
- Employees: 56,000
- 1941 Stryker Way, Portage, MI, 49002, US
- www.stryker.com
Stryker Corporation functions as a prominent medical technology enterprise, with its operations structured across two main divisions. The Orthopaedics and Spine segment specializes in providing implants for joint replacement procedures (including hips and knees), as well as solutions for trauma and extremities surgeries. This division also furnishes a comprehensive suite of spinal implant products, such as cervical, thoracolumbar, and interbody systems, utilized in addressing spinal injuries, deformities, and degenerative conditions. The MedSurg and Neurotechnology division offers an extensive array of products, encompassing advanced surgical equipment, surgical navigation systems, endoscopic and communication tools, patient handling devices, emergency medical apparatus, and critical care disposable items. This segment also deals in reprocessed and remanufactured medical devices, catering to various medical specialties. Furthermore, its neurotechnology offerings include devices for minimally invasive endovascular techniques, instruments for brain and open skull-based surgical interventions, and orthobiologic and biosurgery products like synthetic bone grafts and vertebral augmentation solutions. It also provides specialized minimally invasive products for treating acute ischemic and hemorrhagic strokes, alongside craniomaxillofacial implants, which include cranial, maxillofacial, and chest wall devices, in addition to dural substitutes and sealants. Stryker distributes its diverse portfolio to medical professionals, hospitals, and other healthcare institutions in approximately 75 countries, leveraging its network of company-owned subsidiaries, regional branches, and independent dealers and distributors. Established in 1941, Stryker Corporation is headquartered in Kalamazoo, Michigan.
Data from the stock’s TipRanks forecast page, read 5 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗